UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Amendment No.)*

Altimmune, Inc.

(Name of Issuer)

Common stock, par value \$0.0001 per share (Title of Class of Securities)

> 02155H200 (CUSIP Number)

August 26, 2021 (Date of Event Which Requires Filing of this Statement)

	□ Rule 13d-1(b)
	⊠ Rule 13d-1(c)
	□ Rule 13d-1(d)
class o	emainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a over page.

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

	CUSIP No.	02155H200		13G	Page 2 of 10 Pages			
1	NAME OF REPORTING PERSONS							
	Sphera Funds Management Ltd.							
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)							
(a) □								
3		(b) ⊠						
3	SEC USE ONLY							
4	CITIZENSHI	P OR PLACE	OF ORGANIZATIO	N				
	Israel							
		5	SOLE VOTING POWER					
NUMBE SHAR		6 SHARED VOTING POWER						
BENEFIC	_		3,775,618 (*)					
OWNED EAC		7	SOLE DISPOSITIVE POWER					
REPORT	ING							
PERSON	WITH	8	SHARED DISPOSITIVE POWER					
			3,775,618 (*)					
9	AGGREGAT	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
	3,775,618 (*)	3,775,618 (*)						
10	CHECK IF T	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)						
11								
8.84% (*) (**)								
12	TYPE OF REPORTING PERSON (See instructions)							
	CO							

^(*) The beneficial ownership of the securities reported herein is described in Item 4(a).

^(**) Based on (a) 39,705,884 shares of Common Stock outstanding as of August 10, 2021, as provided in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission (the "SEC") on August 16, 2021, and (b) certain options to purchase shares of Common Stock, held by the Reporting Persons.

	CUSIP No. ()2155H200		13G	Page 3 of 10 Pages		
1	NAME OF REPORTING PERSONS						
	Sphera Global Healthcare GP Ltd.						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) □ (b) ⊠						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
	Israel						
	•	5	SOLE VOTING POWER				
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		6	SHARED VOTING POWER 3,775,618 (*)				
		7	SOLE DISPOSITIVE POWER				
		8	SHARED DISPOSITIVE POWER 3,775,618 (*)				
9	AGGREGATI 3,775,618 (*)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
10	CHECK IF T	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)					
11	PERCENT O	F CLASS RE	PRESENTED BY AM	IOUNT IN ROW 9			
8.84% (*) (**)							
12	TYPE OF REPORTING PERSON (See instructions)						
	СО						

^(*) The beneficial ownership of the securities reported herein is described in Item 4(a).

^(**) Based on (a) 39,705,884 shares of Common Stock outstanding as of August 10, 2021, as provided in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on August 16, 2021, and (b) certain options to purchase shares of Common Stock, held by the Reporting Persons.

	CUSIP No. ()2155H200		13G	Page 4 of 10 Pages		
1	NAME OF REPORTING PERSONS						
	Sphera Global Healthcare Management LP						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) □ (b) ⊠						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
	Israel						
		5	5 SOLE VOTING POWER				
NUMBER SHARE		6	SHARED VOTING POWER				
BENEFICIA	LLY		3,775,618 (*)				
OWNED I EACH		7	SOLE DISPOSITIVE POWER				
REPORTI PERSON W							
PERSON WITH		8	SHARED DISPOSITIVE POWER				
			3,775,618 (*)				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
	3,775,618 (*)						
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9						
8.84% (*) (**)							
12	TYPE OF REPORTING PERSON (See instructions)						
	СО						

^(*) The beneficial ownership of the securities reported herein is described in Item 4(a).

^(**) Based on (a) 39,705,884 shares of Common Stock outstanding as of August 10, 2021, as provided in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC on August 16, 2021 and (b) certain options to purchase shares of Common Stock, held by the Reporting Persons.

Item 1. (a) Name of Issuer: Altimmune, Inc. (b) Address of Issuer's Principal Executive Offices: 910 Clopper Road, Suite 201S, Gaithersburg, MD Item 2. (a) Name of Person Filing: Sphera Funds Management Ltd. Sphera Global Healthcare GP Ltd. Sphera Global Healthcare Management LP (b) Address of Principal Business Office: Sphera Funds Management Ltd. – 21 Ha'arba'ah Street, Tel Aviv 64739, Israel Sphera Global Healthcare GP Ltd – 21 Ha'arba'ah Street, Tel Aviv 64739, Israel Sphera Global Healthcare Management LP – 21 Ha'arba'ah Street, Tel Aviv 64739, Israel (c) Citizenship: Sphera Funds Management Ltd. – Israel Sphera Global Healthcare GP Ltd – Israel Sphera Global Healthcare Management LP – Israel (d) Title of Class of Securities: Common stock, par value \$0.0001 per share **CUSIP Number**: (e) 02155H200

Item 4. Ownership:

Item 3.

(a) Amount beneficially owned:

Not applicable.

See row 9 of cover page of each reporting person.

The securities reported herein by Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd., and Sphera Global Healthcare Management LP are beneficially owned as follows:

- 2,117,080 shares of Common Stock (or options exercisable into shares of Common Stock), representing a total of 4.96% of the total shares of Common Stock outstanding, are held directly by Sphera Global Healthcare Master Fund, which has delegated its investment management authority to Sphera Global Healthcare Management LP (the "Management Company").
- 1,658,538 shares of Common Stock (or options exercisable into shares of Common Stock), representing a total of 3.88% of the
 total shares of Common Stock outstanding, are held directly by Sphera Biotech Master Fund, L.P., which has delegated its
 investment management authority to the Management Company.

The Management Company is managed, controlled, and operated by its general partner, Sphera Global Healthcare GP Ltd., which is controlled by Sphera Funds Management Ltd.

This Statement shall not be construed as an admission by any of the Reporting Persons that it is the beneficial owner of any of the securities covered by this Statement, and each Reporting Person disclaims beneficial ownership of any such securities. In addition, the Reporting Persons and other entities named in this Schedule 13G may be deemed to constitute a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each of the Reporting Persons and other entities named in this Schedule 13G disclaims the existence of any such group.

(b) Percent of class:

See row 11 of cover page of each reporting person

- (c) <u>Number of shares as to which such person has</u>:
 - (i) Sole power to vote or to direct the vote:

See row 5 of cover page of each reporting person

(ii) Shared power to vote or to direct the vote:

See row 6 of cover page of each reporting person and note in Item 4(a) above

(iii) Sole power to dispose or to direct the disposition of:

See row 7 of cover page of each reporting person

(iv) Shared power to dispose or to direct the disposition of:

See row 8 of cover page of each reporting person and note in Item 4(a) above

Ownership of Five Percent or Less of a Class: Item 5. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another: Not applicable. Item 7. <u>Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or</u> Control Person: Not applicable. Item 8. <u>Identification and Classification of Members of the Group</u>: Not applicable. Notice of Dissolution of Group: Item 9. Not applicable. 7

Item 10. <u>Certification</u>:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

August 31, 2021

Sphera Funds Management Ltd.

<u>/s/ Neomi Elpeleg</u> By: Neomi Elpeleg

Title: Chief Financial Officer

Sphera Global Healthcare GP Ltd.

<u>/s/ Neomi Elpeleg</u> By: Neomi Elpeleg

Title: Chief Financial Officer

Sphera Global Healthcare Management LP

<u>/s/ Neomi Elpeleg</u> By: Neomi Elpeleg

Title: Chief Financial Officer

DESCRIPTION EXHIBIT NO.

Joint Filing Agreement by and among the Reporting Persons, dated as of August 31, 2021. Exhibit 1

10

Exhibit 1

Joint Filing Agreement

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Altimmune, Inc.; each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. In accordance with Rule 13d-1(k)(1), the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13G and any amendments thereto with respect to the equity securities (as defined in Rule 13d-1(i)) of the Issuer, beneficially owned by each of them. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13G and any amendments thereto.

This agreement may be executed in any number of counterparts, each of which shall be deemed an original.

August 31, 2021

Sphera Funds Management Ltd.

/s/ Neomi Elpeleg
By: Neomi Elpeleg
Title: Chief Financial Officer

Sphera Global Healthcare GP Ltd.

<u>/s/ Neomi Elpeleg</u>
By: Neomi Elpeleg
Title: Chief Financial Officer

Sphera Global Healthcare Management LP

<u>/s/ Neomi Elpeleg</u>
By: Neomi Elpeleg
Title: Chief Financial Officer